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Abstract
Background: To investigate the risk of second cancer and radiation induced second cancer following prostate
cancer radiotherapy.
Methods: We compared men with radiotherapy only with those treated with radical prostatectomy only and those
with radiotherapy after radical prostatectomy. Cumulative incidences of second cancers were calculated. Cox
analyses were performed to identify determinants influencing second cancer incidence.
Results: Nineteen thousand five hundred thirty eight patients were analyzed. Age and median follow-up differed
significantly with radiotherapy only patients having the highest median age (70.3 years) and radical prostatectomy only
patients the longest median follow-up (10.2 years). Ten-year cumulative incidence of second cancer was 15.9%, 13.2%
and 10.5% for patients with radiotherapy only, radiotherapy after radical prostatectomy and radical prostatectomy only
(p <0.0001). Increasing age and belonging to the radiotherapy only group were associated with a higher risk of second
cancer—no significant increase was seen in radiotherapy after radical prostatectomy patients. A significantly higher rate of
smoking related malignancies, like lung, bladder and non-melanoma skin cancer, was seen in radiotherapy only patients.
Conclusions: No clear increase in radiation induced second cancer was found in patients after radiotherapy for prostate
cancer. Whereas the rate of second cancer was increased in radiotherapy only patients, no such increase was seen in
patients with radiotherapy after radical prostatectomy. The increase of second cancer following radiotherapy only is
highly likely to reflect advanced age and lifestyle habits and comorbidities.
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Background
Radiation induced second cancers (RISC) are rare but
relevant late effects of radiation therapy (RT) [1, 2]. In
principle most of the knowledge regarding RISC is
derived from epidemiological data of atomic bomb survi-
vors, nuclear accidents and database analyses [3]. Since
there are no biological markers available allowing for a
precise discrimination between RISC and non-radiation
induced second cancer (SC), all assessments are based on
epidemiological and/or statistical analysis. In principle,
RISCs are defined as those cancers occurring inside or
close to radiation exposed regions (field congruence) [4]
and after a longer lag time (>10 years in some publications
even >15 years) [5, 6]. However, in real world settings the
determination of SC risks—and especially RISC risks—
after therapeutic exposures is strongly limited by several
factors: Heterogeneous patient cohorts, small sample
sizes, complex influence of confounders and lacking data.
Nevertheless, in case of Hodgkin’s lymphoma and breast
cancer several trials document an increase in SC and RISC
[7–9]. The risk of lung cancer after breast RT is consider-
ably low in non-smokers (Odds ratio 1), however an
increase (25-fold) was detected in smokers [10]. Thus
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RISC in this setting is triggered mainly by synergisms with
a strong confounding factor.
In case of prostate cancer (PCa) patients being long-
term cancer survivors [11] no clear picture emerges
from all available data [12, 13]. Previous reports on the
incidence of RISC using either Surveillance, Epidemi-
ology, and End Results (SEER) or registry information
provide conflicting results, whether after RT an in-
creased risk of SC in PCa patients exists [14–25] or not
[26–28]. With the help of the population-based Munich
Cancer Registry (MCR) we attempted to gain further
insight into SC risk after RT of PCa.
Methods
Data collection
The MCR is a population-based clinical cancer registry
in Bavaria (Southern Germany) comprising 4.6 million
inhabitants [29]. A total of 42,449 patients with PCa
were registered from 1988 to 2008 (Fig. 1). Patients with
lymphoma (n = 5) or sarcoma (n = 5) of the prostate, or
with death certificate only (DCO) (n = 2,627) and men
with evidence of a previous or synchronous malignant
tumor (n = 4,217) were excluded. Of 35,595 patients with
invasive PCa, 14,289 received radical prostatectomy
(RPE only), 3,883 received radiation therapy (RT only)
and 1,366 got radiation therapy after radical prostatec-
tomy (RT after RPE). All analyses were performed on
19,538 patients (RPE only, RT only or RT after RPE).
This analysis was in conformity with the Declaration of
Helsinki (Sixth Revision, 2008) and was exempt from
ethics approval. Bavarian state law allows the use of
patient data for research, provided that person related
data are made anonymous.
Statistical analysis
The MCR organizes data in an Oracle database (Oracle,
Belmont, CA) and uses Statistical Analysis Software,
version 9.2 (SAS Institute, Cary, NC). The percentages
of the presented subcategories are related to the sum of
each item with available data; missing values are not
taken into account. The significance level was set at 5%.
Median follow-up was calculated for patients alive. To
account for competing risks (e.g. death), the different
age distribution between the three treatment groups and
differences in follow-up cumulative incidence function
according to Kalbfleisch and Prentice was used to calcu-
late time to SC. Cancers occurring within the first year
after treatment for PCa were not considered as SC.
Differences in cumulative incidence among the three
treatment groups were assessed by Gray’s test. Independ-
ent prognostic factors influencing time to SC were inves-
tigated by Cox proportional hazard regression. The
proportional hazard assumption was visually checked by
log-log plots. Hazard ratios, 95% confidence intervals
(CI) and p-values acquired by Global Wald test are
presented. The following factors were included simultan-
eously as independent variables modeling the incidence
of SC in total in the multivariate analysis: age (<60, 60 –
<65, 65 – <70, 70 – <75, ≥75 years), T- (T1, T2, T3, T4),
N- (N0, N+, NX) and M-category (M0, M1) and treat-
ment (RPE only, RT only and RT after RPE). Cox
proportional hazard regression was also used to calculate
models for the incidence of the most common tumor
entities adjusted for the covariates mentioned above.
Results
Overall cumulative incidence and location of second
cancer
Table 1 lists the characteristics of the cohort with RT
only or with RT after RPE compared to the surgical
control group (RPE only). Patients with RT only had a
higher median age (70.3 years) than patients with RPE
only (65.2 years) or RT after RPE (64.4 years). Tumor
characteristics were equally distributed between the
three groups. Median follow-up between the three
groups was significantly different with 10.2, 9.6 and
8.8 years in patients with RPE only, RT only and RT after
RPE. Since previous studies on atomic bomb survivors
estimated an average latency time of 5–15 years for
RISC, analyses were done for SC occurring >10 years
and >20 years [5, 6]. The cumulative incidence of SC
was 15.9%, 13.2% and 10.5% after 10 and 26.7%, 26.6%
and 23.7% after 20 years for patients with RT only, RT
after RPE and RPE only (p <0.0001). The most frequent
sites of SC were colon, rectal, lung, bladder and non-
melanoma skin cancer (Table 2) significantly differently
distributed between the treatment groups. After 10 years,
colon cancer was observed with a cumulative incidence
of 2.0% in RT after RPE followed by RT only (1.7%) and
RPE only (1.1%) (Fig. 2a). Rectal cancer occurred more
often in RT only (1.1%) than in RPE only (0.6%) and RT
Fig. 1 Patient cohort. DCO = death certificate only
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after RPE (0.3%) (Fig. 2a). The cumulative incidence of
lung cancer was 2.2% after RT only and 1.2% in surgical
patients regardless of postoperative RT (Fig. 2b). Bladder
cancer was seen with a cumulative incidence of 2.7%,
1.5% and 1.1% in RT only, RT after RPE and RPE only
(Fig. 2c). Non-melanoma skin cancer was observed with
a cumulative incidence of 2.1%, 1.6% and 1.2% in RT
only, RT after RPE and RPE only (Fig. 2d).
Factors influencing incidence of second cancer
Table 3 shows the results of the Cox analysis for SC in
total with age, T-, N- and M-category and treatment as
influencing factors. Age, T- and N-category and treat-
ment were predictors for SC development. Increasing
age was significantly associated with a higher risk of SC.
RT only patients remained at a significantly higher risk
of SC (HR1.404) compared to patients with RPE only
(HR 1) or RT after RPE (HR 1.314). Already metastasized
patients at initial treatment were at lower risk of SC due
to their shortened life span. Analyzing the most frequent
sites of SC separately adjusted for the abovementioned
confounder variables treatment group remained a sig-
nificant factor (Table 4). RT after RPE patients were at
the highest risk of developing colon cancer compared to
the other two treatment groups. Regarding rectal cancer,
RT only patients (HR 1.751) were at highest risk and
patients with RT after RPE were less at risk (HR 0.638)
compared to RPE only patients (HR 1). RT only patients
were at high risk (HR 1.733) of lung cancer during
follow up. Hazard ratios regarding lung cancer of pa-
tients with RPE only (HR 1) or RT after RPE (HR 1.017)
did not differ: Fig. 2b demonstrates no difference in
cumulative probability of lung cancer after 10 years be-
tween patients with RPE only or RT after RPE. Likewise
the risk of bladder cancer was significantly higher for RT
only patients (HR 2.098) in contrast to a lower probabil-
ity in patients with RPE only (HR 1) or RT after RPE
(HR 1.601) (Fig. 2c). This was also observed for non-
melanoma skin cancer (Fig. 2d) with RT only patients
(HR 1.658) being at highest risk compared to the other
two treatment arms (HR RPE only 1 and HR RT after
RPE 1.305). Analysis of the most frequent sites of SC
revealed a significantly increased rate of smoking and
age related cancer entities, like lung, bladder and non-
melanoma skin cancer in RT only patients.
Discussion
The present study compares the incidence of SC in
patients treated with RT only or RT after RPE to a surgi-
cal control group (RPE only). Two key findings emerged:
First, the rate of smoking related cancer entities is
increased in RT only patients but not in patients with
RT after RPE. Secondly, patients who do receive RT
as curative treatment are generally older probably
Table 1 Patient characteristics
Treatment RPE only RT only RT after RPE
N % N % N %
All 14289 100.0 3883 100.0 1366 100.0
Age [yrs]
median 65.2 70.3 64.4
< 60 3208 22.5 367 9.5 356 26.1
60–64 3758 26.3 599 15.4 364 26.6
65–69 4391 30.7 903 23.3 412 30.2
70–74 2432 17.0 1135 29.2 199 14.6
> =75 500 3.5 879 22.6 35 2.6
Risk Group
low riska 1843 13.2 529 17.0 35 2.6
intermediate riskb 3051 21.9 665 21.4 162 12.1
high riskc 6130 44.1 1067 34.3 504 37.8
locally advancedd 2615 18.8 738 23.8 522 39.1
advanced (N+) 275 2.0 108 3.5 112 8.4
metastasized (M1) 54 0.4 401 11.4 20 1.5
Missinge 321 2.2 375 9.7 11 0.8
T-category
T1 1852 13.4 586 19.2 146 10.9
T2 9152 66.0 1508 49.5 563 42.1
T3 2724 19.6 784 25.7 565 42.3
T4 139 1.0 170 5.6 62 4.6
Missinge 422 3.0 835 21.5 30 2.2
N-category
N0 9008 65.2 2046 67.3 869 64.6
N+ 346 2.5 198 6.5 128 9.5
NX 4460 32.3 794 26.1 348 25.9
Missinge 475 3.3 845 21.8 21 1.5
M-category
M0 14235 99.6 3482 89.7 1346 98.5
M1 54 0.4 401 10.3 20 1.5
Second Cancer (p < 0.0001)
developed 1876 638 186
CI after 10 years 10.5 15.9 13.2
CI after 20 years 23.7 26.7 26.6
Median follow-up of survivors [yrs] (p < 0.0001)
10.2 9.6 8.8
CI cumulative incidence
alow risk: PSA ≤ 10 ng/ml and Gleason score ≤ 6 and T1 to T2a (without T2)
bintermediate risk: PSA >10 – 20 ng/ml or Gleason = 7 or T2b
chigh risk: PSA > 20 ng/ml or Gleason score ≥ 8 or T2c
dlocally advanced: T3-4
eThe percentage of the subcategories is related to the sum of each item with
available data; missing values are not taken into account
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harboring more comorbidities than patients undergoing
surgery [30]. This implies that there are more con-
founders than age, T-, N- and M-category and treatment
that influence the differing incidence of SC between the
three treatment arms.
In accordance with literature [14–16, 18, 19, 24], an
increased incidence of SC after 10 years has been seen
in RT only patients (15.9%) vs. patients with RPE only
(10.5%) or RT after RPE (13.2%). Differences in SC inci-
dence between the cohorts should not be attributed to
different median follow-up, as this has been taken into
account by calculating cumulative incidence rates
according to Kalbfleisch and Prentice. The cumulative
incidence function by Kalbfleisch and Prentice does not
only consider different follow up time but also considers
the different age distribution between the three treat-
ment groups and death as a competing risk factor. Cox
analysis revealed that especially increasing age and being
treated by RT only are the main predictive factors for a
higher overall SC incidence.
Table 2 Cumulative incidencea of most common cancer entities after 10 years of follow-up
RPE only [%] RT only [%] RT after RPE [%] p-value*
All second cancer 10.5 15.9 13.2 <.0001
Colon cancer 1.1 1.7 2.0 0.0017
Rectal cancer 0.6 1.1 0.3 0.0036
Lung cancer 1.2 2.2 1.2 <.0001
Bladder cancer 1.1 2.7 1.5 <.0001
Non-melanoma skin cancer 1.2 2.1 1.6 <.0001
aTo account for competing risks, like death, cumulative incidence analysis was used to calculate time to second malignancy
*p-value was calculated by Gray-Test
Fig. 2 a-d Cumulative incidences of colorectal, lung, bladder and non-melanoma skin cancer stratified by treatment arms (RPE only, RT only, RT after RPE)
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When analyzing the situation for those SC sites in
close proximity to the radiation portals (rectal, colon
and bladder cancer) a complex picture emerges: At first
glance, the rate of SC is increased after RT only – how-
ever no such increase is detectable in patients receiving
both RPE and RT with the lowest absolute rate of rectal
cancer being visible in patients having had both treat-
ments. Based on pure reasoning, it seems therefore un-
likely that radiation is really causal for the observed
effect in RT only patients. The low number of events
even in a large cohort will limit any valid risk assess-
ment: In patients with RT only (HR 1.751) there was a
70% higher risk of rectal cancer compared to patients
treated with RPE only (HR 1) and a less increased risk of
colon cancer (HR 1.326 for RT only vs. HR 1 for RPE
only). The diverging HRs of patients with RT after RPE
with decreased risk of rectal (HR 0.638) and increased
risk of colon cancer (HR 1.903) can be partially ex-
plained by the few events in the small group of patients
with RT after RPE, which can also be seen in the wide
95% CI. Similarly, most other trials were not able to un-
equivocally document any increase in the incidence of
colorectal cancer after RT [17, 25–27, 31–33]. Kendal et
al. reported that an increased frequency of rectal cancer
after irradiation is apparent on crude analysis, but age as
an important confounder has to be taken into account.
After adjustment for age these differences were no lon-
ger observable [26, 32]. Globally, our Cox regression
analysis also revealed that age as a covariate generally
plays a significant role in the development for SC at any
site including colorectal SC (Hazard Ratio 1.278 in 60 -
<65 year old patients vs. 2.177 in ≥75 year old patients,
p <0.0001). Taken together our data do not indicate that
RT is associated with a relevant risk of SC induction in
the colorectum.
Similar to the colorectal mucosa variable parts of the
bladder are exposed to radiation. Thus the bladder is
also at risk for RISC. In our trial the 10-year cumulative
incidence of bladder cancer was low with 2.7% in RT
only, 1.5% in postoperative RT and 1.1% in RPE only
patients. Cox analysis revealed that the RT only group
(HR 2.098) had the highest risk of bladder cancer
Table 3 Cox proportional hazard model for second cancer with
age, T-, N- and M-category and treatment as independent covariates
Patients: n = 19,538 Events: n = 2,700
Covariates HR 95%-CI p-value*
Age [yrs] <0.0001
< 60 1
60–<65 1.278 1.124 1.453
65–<70 1.618 1.434 1.826
70–<75 2.136 1.881 2.425
> =75 2.177 1.836 2.581
T-category 0.0023
T1 1.089 0.964 1.231
T2 1
T3 1.204 1.095 1.324
T4 1.086 0.786 1.501
Missing 1.221 0.985 1.514
N-category 0.0120
N0 1
N+ 1.095 0.863 1.388
NX 0.965 0.885 1.052
Missing 1.373 1.117 1.688
M-category 0.6458
M0 1
M1 0.913 0.619 1.346
Treatment <0.0001
RPE only 1
RT only 1.404 1.268 1.553
RT after RPE 1.314 1.127 1.531
HR Hazard Ration, CI confidence interval
*p-value (Linear hypothesis test or Global Wald test)
Table 4 Cox proportional hazard model for selected second
cancer entities adjusted for age, T-, N- and M-category and
treatment as independent covariates




RT only 1.326 0.970 1.813
RT after RPE 1.903 1.269 2.853
Rectal cancer 0.0077
RPE only 1
RT only 1.751 1.179 2.601
RT after RPE 0.638 0.278 1.465
Lung cancer 0.0011
RPE only 1
RT only 1.733 1.293 2.324
RT after RPE 1.017 0.598 1.730
Bladder cancer
RPE only 1 <0.0001
RT only 2.098 1.585 2.778
RT after RPE 1.601 1.001 2.561
Non-melanoma skin cancer
RPE only 1 0.0020
RT only 1.658 1.246 2.205
RT after RPE 1.305 0.802 2.124
HR Hazard Ration, CI confidence interval
*p-value (linear hypothesis test or Global Wald test)
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compared to the surgically treated patients. Similar to
the findings for colorectal SC, combined treatment was
associated with a lower incidence of bladder SC com-
pared to RT only. Thus again our data failed to docu-
ment an unequivocal increase in bladder RISC. In
contrast the SEER analysis of Singh et al. showed a sig-
nificant difference in the crude incidence rate of bladder
cancer when comparing RT vs. surgery alone. On multi-
variate analysis in this study, age and irradiation were
highly significant predictors of being diagnosed with
bladder cancer [20]. As smoking data are absent from
the SEER database, it was not possible to adjust for this
confounder. In a recent report, Zelefsky et al. presented
the 10-year likelihood rates for bladder cancer in pa-
tients treated with RPE or RT. One of the key messages
of this trial is that patients treated with RT were older
and had more serious comorbidities, many of them re-
lated to smoking. After Cox regression analysis, only age
and history of smoking were significant predictors for
the development of SC in this trial [27]. Likewise,
Hamilton et al. came to a similar conclusion after
comparing patients with brachytherapy and radical
prostatectomy to the general population [34]: Older
age and smoking were associated with an increased
SC risk. Radical prostatectomy was not associated
with a decreased pelvic malignancy risk, even when
excluding patients with post-prostatectomy RT.
In addition to SC in close proximity to the primary ra-
diation fields, several groups also explored the rate of SC
outside the direct treatment areas.
In a recent report, Donin et al. presented the most
common sites of SC among cancer survivors from SEER
database [35]. Like in our cohort, the most commonly
diagnosed SC among PCa survivors was lung (20.1%),
colorectal- (15.5%) and bladder cancer (13.2%). Thus,
smoking related cancers dominate the SC rates. A short-
coming of the data by Donin et al. is the missing correl-
ation of SC rate with the respective treatment. The
cumulative incidence of lung cancer in our cohort was
2.2% after RT only whereas it was the same (1.2%) in
patients with RPE only or RT after RPE. Thus again, our
data substantially indicate that SC in patients with RT
only is related to a strong selection bias rather than indi-
cating a real risk of SC after RT. Mainly patients being
not fit for surgery will be selected for RT with smoking
related disorders and age being major reasons [30, 36].
Smoking habits were not uniformly registered in MCR
and could therefore not be used in the Cox analysis. We
can therefore only hypothesize that smoking prevalence
and its related comorbidities were higher in the generally
older RT only patients. Depending on the prevalence,
tobacco use alone could account for the observed 1.0%
increase in cumulative incidence of lung cancer seen in
the RT only group [37].
Apart from the abovementioned cancer entities, a sin-
gle report documented an increase of non-melanoma
skin cancer: Zelefsky et al. showed higher rates of skin
cancer in patients with external beam RT compared to
the general population or to patients who received
brachytherapy. Apparently this is due to low-dose radi-
ation from internally scattered X-rays, leakage of X-rays
from the machine and/or neutron production, especially
observed after doses ≥10 MV photons [38]. Apart from
skin cancer Zelefsky et al. could not find any excessive
risk of SC [21]. In contrast, no such increase was detect-
able in the RT after RPE group from our analysis indicat-
ing that the small increase in non-melanoma skin cancer
in RT only patients may be attributed to other factors
than the use of RT [39].
The high complexity of interacting confounding fac-
tors can be seen when the data of the large Prostate,
Lung, Colorectal and Ovarian Cancer (PLCO) screening
trial is taken into account: At first glance, patients after
RT had increased risks for any SC (incidence 15.5/1000
person-years in irradiated patients vs. 11.4/1000 person-
years in non-irradiated patients) with a substantial in-
crease in lung cancer (RR 1.6, 95% CI 1.1-2.4). However,
after adjusting for age, race, education, family history of
cancer, COPD and smoking no increase for second colo-
rectal or bladder cancer was documented any longer.
Based on simple reasoning, it seems highly unlikely that
no such increase occurs in close proximity to the radi-
ation exposure, whereas a substantial increase occurs in
far distant regions with only minimal radiation exposure.
This interpretation is corroborated further by the fact
that after breast irradiation with relevant part of the
lungs being exposed, only a very low risk of SC is docu-
mented in non-smokers [10].
Most studies on RISC are based on pooled data sets.
Inherently biases and confounders blur the interpret-
ation of these results. A Dutch group analyzed the
incidence rate of SC for patients prospectively treated in
the TME trial, the PORTEC-1 and PORTEC-2 trial. The
number of events (SCs) was much lower and however
no significant increase for any pelvic or non-pelvic RISC
was found [33].
All in all, up to now no consistent increased risk for
SC after RT has been published. Most trials, like ours
are based on retrospective data analyses with inherent
shortcomings: Major confounders (e.g. smoking habits)
have not been documented, treatment decisions (RT vs.
no-RT) are mainly based on subjective and ill-defined
parameters leading to strong biases, radiobiological in-
consistences exist with patient receiving a combined
treatment of RT and surgery displaying the lowest rate
of SC in some data sets and crude SC rates outside the
radiation fields are higher than in close proximity to the
exposed areas. With RT only patients having the highest
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number of SC cumulative incidence, a correlation be-
tween dose and SC incidence in patients treated with RT
only or with RT after RPE with assumingly different
overall doses would have been interesting. Unfortunately
in the MCR only limited information regarding the type
of radiation delivery, the dosage and fields is given. We
tried to overcome these shortcomings by using the cu-
mulative incidence function according to Kalbfleisch and
Prentice as an elaborate statistical method that accounts
for death as a competing risk factor, the different age
distribution and differences in follow-up between the
three treatment arms.
In this regard a commentary from Kendal et al. on
data provided by Moon et al. [40] nicely summarizes all
these shortcomings with his own observation that no
increase of RISC is detectable in 520,708 SEER cases
with PCa after appropriate statistical considerations of
age shifts (attained age) and other major factors [32].
Accordingly, Murray et al. [1] also pinpoints that differ-
ences between comparison groups, as well as differences
in length of follow-up between treatment groups and
failure to adequately correct for duration of follow-up
may result in inaccurate conclusions.
Conclusions
Our data suggest that RT does not increase the risk of SC.
The increase of SC seen in patients with RT only in our
cohort needs to be attributed to confounders suggested by
an increased rate of smoking related malignancies. This
interpretation is corroborated by the fact that no such
increase was seen in patients treated with RT after RPE.
At present we do recommend to inform patients about
the negligible risk. However, it seems extremely important
to ensure that the information given enables patients to
realistically balance the value of the treatment against the
risks. For any future trial it seems mandatory to carefully
and prospectively document confounding comorbidities
and lifestyle habits when attempting to gain a detailed and
realistic insight into the risk of SC in PCA patients.
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